The Evolving Role of Tucatinib in HER2-Positive Metastatic Breast Cancer
A key opinion leader discusses how the role tucatinib is evolving in the management of HER2-positive metastatic breast cancer.
Watch
Evaluating CPI-0610 as Treatment of Patients With Myelofibrosis
Srdan Verstovsek, MD, PhD, discusses the potential role of CPI-0610 as treatment of patients with myelofibrosis.
Investigators Observe Differences in Toxicity for Sarcoma Due to Dosing
Gary K. Schwartz, MD, discusses adverse events seen in patients with metastatic sarcoma participating in the Alliance A091401 trial.
Future Directions in High-Risk Ovarian Cancer
Rucaparib Maintenance Therapy for High-Risk Ovarian Cancer
Maintenance Therapy for Advanced Ovarian Cancer
Rucaparib for Relapsed Ovarian Cancer: Safety Profile
Rucaparib: Clinical Activity in Relapsed Ovarian Cancer
Rucaparib Explored for High-Risk Ovarian Cancer
Advanced Ovarian Cancer Treatment Strategies
Outlook for Patients With High-Risk Ovarian Cancer
Case Overview: High-Risk Ovarian Cancer
A 71-Year-Old Woman With High-Risk Ovarian Cancer
Ramez N. Eskander, MD, explains the rationale for treating a 71-year-old woman with ovarian cancer with the PARP inhibitor rucaparib upon relapse.
CAR T-Cell Therapy Evolves in Leukemia Treatment Landscape
Jae H. Park, MD, discusses the role of chimeric antigen receptor T-cell therapy in leukemias and how he sees this treatment evolving in the coming years.
Discussing Recent Advances and Clinical Trials in Bladder Cancer
Matthew Galsky, MD, discusses the most recent data in patients with bladder cancer.
Multikinase Inhibitor Overall Survival Advantage
Radioiodine-Refractory DTC: NCCN Guidelines
What is Radioiodine-Refractory DTC?
SELECT Trial: Toxicity, Duration of Response, and Dose Reduction
Phase 3 SELECT Trial Overview
Radioiodine Refractory Differentiated Thyroid Carcinoma
A key opinion leader discusses the evolving treatment landscape for radioiodine refractory differentiated thyroid carcinoma, with special consideration of the phase 3 SELECT trial.
Optimizing Therapy for Advanced Cholangiocarcinoma
Advanced Cholangiocarcinoma: FGFR2 Inhibitors vs Chemo
FGFR2 Inhibitors in Advanced Cholangiocarcinoma
Driver Mutations in Advanced Cholangiocarcinoma
Advanced Cholangiocarcinoma: Current Treatment Landscape
Committee Helps Physician's Find Best Options for Patients Through NGS
Jennifer Marie Suga, MD, discusses how the results from next-generation sequencing tests are assessed to help physicians manage their patients in real-time.
Role of Targeted Therapies in Advanced Cholangiocarcinoma
Saeed Sadeghi, MD, comments on the utilization of FGFR2 inhibitors as treatment for advanced cholangiocarcinoma.
Evaluating the Role of EGFR Mutations in the Treatment of Advanced NSCLC
Balazs Halmos, MD, MS, discusses the role of EGFR mutations in patients with advanced non—small cell lung cancer.
Sequencing Therapies in the First and Second Line for Patients With HCC
Lipika Goyal, MD, discusses first-line options for patients with patients with hepatocellular carcinoma.